低危前列腺癌的风险分层:主动监测时代的个体化治疗
本文为非系统性文献综述,检索至2023年1月的PubMed文献,评估低危前列腺癌男性风险分层的临床、病理、分子和影像学工具。癌总体积、PSA密度和导管成分与当前或未来更高分级疾病强相关;PSA动力学、MRI上前列腺影像报告和数据系统4/5病变、神经周围侵犯、胚系突变和基因组分类器似乎与风险增加相关但验证不广泛;种族、游离PSA百分比和前列腺健康指数、4Kscore等血清标志物似乎与长期风险升高无关。
要点
- 癌总体积、PSA密度和导管成分与更高分级疾病强相关。
- PSA动力学、MRI前列腺影像报告和数据系统4/5病变、神经周围侵犯、胚系突变和基因组分类器似乎与风险增加相关。
- 种族、游离PSA百分比、前列腺健康指数和4Kscore似乎与长期风险升高无关。
核心结论
- 低危前列腺癌男性长期预后极好,应常规整合多种因素到初始治疗决策及主动监测强度和频率的确定中,并鼓励开发综合多变量工具指导临床决策。
研究设计与样本
- 非系统性文献综述,检索PubMed截至2023年1月,纳入低危前列腺癌男性风险评分的临床、病理、分子和影像学相关文章,由作者审阅并总结证据。
主要发现
- 癌总体积、PSA密度和导管成分的存在与当前或未来更高分级疾病的证据持续且强相关。
- PSA动力学、MRI上前列腺影像报告和数据系统4/5病变、神经周围侵犯、胚系突变和基因组分类器似乎与风险增加相关,但验证不如前者广泛。
- 种族、游离PSA百分比以及前列腺健康指数和4Kscore等其他血清生物标志物似乎与长期风险升高无关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: While active surveillance is the preferred management for most men with low-risk prostate cancer, a subset may harbor more aggressive disease. In this review we examine the evidence underlying an accurate and nuanced assessment of oncologic risk in these men. MATERIALS AND METHODS: We performed a nonsystematic literature review current to January 2023 on PubMed for articles relating to clinical, pathological, molecular, and imaging-based modalities available for risk assessment in men with low-risk prostate cancer. Relevant articles were reviewed by the authors and evidence was summarized. RESULTS: Many tools are available to personalize clinical decision-making for men with low-risk prostate cancer. Total volume of cancer, PSA density, and presence of ductal components have been consistently and strongly associated with current or future evidence of higher-grade disease. PSA kinetics, Prostate Imaging Reporting & Data System 4/5 lesions on MRI, perineural invasion, germline mutations, and genomic classifiers all appear to be associated with an increased risk, although are not as extensively validated. Race, percent free PSA, and other serum biomarkers such as Prostate Health Index and 4Kscore do not appear to be associated with long-term elevated risk. CONCLUSIONS: Long-term prognosis for men diagnosed with low-risk prostate cancer is excellent. There are many factors which should be routinely integrated into the initial management decision as well as determining intensity and frequency of active surveillance. Development of comprehensive multivariable instruments to guide clinical decisions is encouraged.
引用
- Ho MD, Ross AE, Eggener SE, et al. Risk Stratification of Low-risk Prostate Cancer: Individualizing Care in the Era of Active Surveillance. J Urol. 2023. PMID: 37042807. doi:10.1097/JU.0000000000003454
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。